Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Négrier, Sylvie, Pérol, David, Bahleda, Rastislav, Hollebecque, Antoine, Chatelut, Etienne, Boyle, Helen, Cassier, Philippe, Metzger, Séverine, Blanc, Ellen, Soria, Jean-Charles, Escudier, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558713/
https://www.ncbi.nlm.nih.gov/pubmed/28810837
http://dx.doi.org/10.1186/s12885-017-3527-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558713/
https://www.ncbi.nlm.nih.gov/pubmed/28810837
http://dx.doi.org/10.1186/s12885-017-3527-7

Ejemplares similares